PSC: Can Recurrent Cholangitis Raise My MELD Score?
At a Glance
PSC patients who suffer from recurrent bacterial cholangitis may qualify for a MELD score exception if standard lab tests don't reflect their severity of illness. Documenting frequent hospitalizations for IV antibiotics helps transplant teams petition for higher waitlist priority.
In this answer
4 sections
Can frequent bile duct infections help me get a liver transplant sooner? It is possible. For patients with Primary Sclerosing Cholangitis (PSC) who suffer from recurrent bacterial cholangitis, the transplant system offers a pathway called a MELD score exception [1]. Because standard MELD scores often fail to capture the debilitating nature of frequent, life-threatening bile duct infections, you may qualify for extra points that move you higher up the transplant waiting list [2][3].
Understanding Standard MELD vs. MELD Exceptions
In the United States, liver transplants are allocated based primarily on a patient’s MELD score (Model for End-Stage Liver Disease) [4].
- Standard MELD 3.0: This is a calculated number based on routine blood tests (bilirubin, INR, creatinine, sodium, and albumin) as well as the patient’s sex/gender, which estimates the risk of mortality within 90 days [1].
- The Problem for PSC Patients: Because PSC primarily affects the bile ducts, a patient’s liver function may appear relatively healthy on paper between infection flare-ups [2]. This means your raw lab numbers might result in a low MELD score that vastly underestimates your actual illness, poor quality of life, and risk of severe infection [3][5].
- MELD Exceptions: To account for this, the Organ Procurement and Transplantation Network (OPTN) and the National Liver Review Board (NLRB)—a national committee that reviews transplant applications—grant “exception points” for specific conditions [4][6]. These points are awarded when the standard lab-based MELD fails to reflect a patient’s true clinical urgency [7].
Criteria for a Recurrent Cholangitis Exception
Recurrent bacterial cholangitis (frequent bacterial infections of the bile ducts) is officially recognized as a condition that may qualify for an exception [8]. To be approved, your transplant team must submit a detailed petition to the NLRB [9]. The board typically reviews these petitions within a few weeks.
While review boards look at the full clinical picture, successful applications generally demonstrate:
- Frequent Severe Infections: A documented history of multiple severe cholangitis episodes (frequently defined as at least two within a six-month period) characterized by fever, abdominal pain, and jaundice [10].
- Hospitalization and IV Antibiotics: These episodes must be severe enough to require hospital admission and treatment with intravenous (IV) antibiotics, showing that oral medications at home were insufficient [11][12].
- Absence of a Treatable Blockage: Your medical team must show that these infections are not being caused by a dominant stricture (a severe narrowing in a main bile duct) that could easily be fixed with an endoscopic procedure, such as an ERCP to place a stent [13][14].
- What if a stricture is found? If a stricture can be treated, that must be attempted first. However, if your doctor treats the stricture but you continue to suffer from severe infections, you may still qualify for an exception [15].
How Exception Points Affect Your Waitlist Status
If the NLRB approves your doctor’s petition, you are typically awarded points based on the Median MELD at Transplant (MMaT) in your region, minus 3 points (referred to as MMaT-3) [16][17].
- What this means: Instead of using your calculated lab-based MELD score (which might be as low as 12 or 15), you will be assigned a score just three points below the average score of people currently receiving liver transplants in your area [18].
- The Impact: This significantly bumps up your priority on the waitlist, providing much faster access to a life-saving transplant while correcting for geographical disparities [19][20].
- Renewals and Updates: Once granted, these exception points do not last indefinitely. Your transplant team must submit a renewal application to the NLRB periodically (typically every 90 days) to prove you still need the exception. Additionally, the OPTN updates the MMaT twice a year, meaning your exact exception score might fluctuate slightly while you wait.
Tracking and Advocacy
Because exceptions rely heavily on clinical history rather than just routine lab draws, detailed documentation is crucial [10].
- Keep meticulous records: Track every fever, chill, hospital admission, and round of antibiotics in a dedicated medical spreadsheet or notebook.
- Collect discharge summaries: If you are treated for an infection at a local ER rather than your main transplant center, be sure to request the discharge summaries and lab results to give to your transplant coordinator.
- Communicate clearly: Make sure your transplant hepatologist understands exactly how these infections are impacting your ability to function, as they will need this evidence to strongly advocate on your behalf [9][21].
Common questions in this guide
What is a MELD score exception for PSC?
How many bile duct infections do I need to qualify for a MELD exception?
Will a treatable bile duct stricture prevent me from getting an exception?
What is MMaT-3 and how does it affect my transplant waitlist score?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Do my recent bile duct infections and hospitalizations meet the NLRB criteria to apply for a MELD exception?
- 2.Are there any dominant strictures we need to treat or rule out before submitting an exception petition?
- 3.What is the current Median MELD at Transplant (MMaT) in our region, and what would my waitlist score be if an exception is granted?
- 4.How long does the National Liver Review Board typically take to review your petitions, and what happens if we are denied?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (21)
- 1
Outcomes of Liver Transplant Recipients With Model for End-Stage Liver Disease Exception: Single-Center Experience in the Northeast of Brazil.
Coelho GR, Praciano AM, Viana GNR, et al.
Transplantation proceedings 2018; (50(5)):1428-1430 doi:10.1016/j.transproceed.2018.03.003.
PMID: 29880366 - 2
Liver transplantation for cholestatic liver diseases: Timing and disease recurrence.
Cançado GGL, Deeb M, Gulamhusein AF
Hepatology (Baltimore, Md.) 2025; (82(4)):1016-1035 doi:10.1097/HEP.0000000000001268.
PMID: 39960305 - 3
A Critical Review of MELD as a Reliable Tool for Transplant Prioritization.
Sacleux SC, Samuel D
Seminars in liver disease 2019; (39(4)):403-413 doi:10.1055/s-0039-1688750.
PMID: 31242526 - 4
Liver transplant allocation policies and outcomes in United States: A comprehensive review.
Latt NL, Niazi M, Pyrsopoulos NT
World journal of methodology 2022; (12(1)):32-42 doi:10.5662/wjm.v12.i1.32.
PMID: 35117980 - 5
Evaluation and management of primary sclerosing cholangitis patients awaiting liver transplantation.
Frolkis AD, Nayagam JS, Parente A, et al.
JHEP reports : innovation in hepatology 2026; (8(4)):101748 doi:10.1016/j.jhepr.2026.101748.
PMID: 41825099 - 6
Changing prioritization for transplantation: MELD-Na, hepatocellular carcinoma exceptions, and more.
Kalra A, Wedd JP, Biggins SW
Current opinion in organ transplantation 2016; (21(2)):120-6 doi:10.1097/MOT.0000000000000281.
PMID: 26825358 - 7
Model for end-stage liver disease score and MELD exceptions: 15 years later.
Asrani SK, Kamath PS
Hepatology international 2015; (9(3)):346-54 doi:10.1007/s12072-015-9631-3.
PMID: 26016462 - 8
Exception points for liver transplantation: A Canadian review.
Congly SE, Marquez V, Bhanji RA, et al.
Canadian liver journal 2023; (6(2)):201-214 doi:10.3138/canlivj-2022-0026.
PMID: 37503519 - 9
Liver Allocation Policies in the USA: Past, Present, and the Future.
Pillai A, Couri T, Charlton M
Digestive diseases and sciences 2019; (64(4)):985-992 doi:10.1007/s10620-019-05549-y.
PMID: 30895482 - 10
Recurrent cholangitis after choledochoduodenostomy: A case report.
Uwuratuw JA, Bakhtiar B, Labeda I, et al.
International journal of surgery case reports 2022; (92()):106912 doi:10.1016/j.ijscr.2022.106912.
PMID: 35248882 - 11
Recurrent Bacteremia and Cholangitis From Eroded Hepatic Artery Pseudoaneurysm Coil Into the Common Hepatic Duct: A Rare Indication for Liver Transplantation.
Wang MC, Bui A, Tintara S, et al.
ACG case reports journal 2025; (12(1)):e01590 doi:10.14309/crj.0000000000001590.
PMID: 39790174 - 12
Long-term kidney and liver outcome in 50 children with autosomal recessive polycystic kidney disease.
Dorval G, Boyer O, Couderc A, et al.
Pediatric nephrology (Berlin, Germany) 2021; (36(5)):1165-1173 doi:10.1007/s00467-020-04808-9.
PMID: 33165639 - 13
Healthy Donor Fecal Microbiota Transplantation for Recurrent Bacterial Cholangitis in Primary Sclerosing Cholangitis - A Single Case Report.
Philips CA, Augustine P, Phadke N
Journal of clinical and translational hepatology 2018; (6(4)):438-441 doi:10.14218/JCTH.2018.00033.
PMID: 30637223 - 14
Recurrent cholangitis in patients with a non-stenotic hepaticojejunostomy: incidence and risk factors.
Overdevest AG, Fritzsche JA, Smit MAD, et al.
HPB : the official journal of the International Hepato Pancreato Biliary Association 2024; (26(4)):558-564 doi:10.1016/j.hpb.2024.01.003.
PMID: 38245491 - 15
Primary antibiotic prophylaxis in biliary atresia did not demonstrate decreased infection rate: Multi-centre retrospective study.
Brody Y, Slae M, Amir AZ, et al.
Acta paediatrica (Oslo, Norway : 1992) 2025; (114(3)):654-659 doi:10.1111/apa.17493.
PMID: 39528247 - 16
Liver allocation exception policies for calculating median model for end-stage liver disease at transplant need to be updated to reflect changes in practice.
Marsh A, Shah M, Karp S, Goldberg DS
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2026; (26(5)):944-949 doi:10.1016/j.ajt.2025.12.007.
PMID: 41391785 - 17
Changing opportunities for liver transplant for patients with hepatocellular carcinoma.
Zendel A, Watkins R, Moon AM, et al.
Clinical transplantation 2022; (36(5)):e14609 doi:10.1111/ctr.14609.
PMID: 35137467 - 18
Impact of major hepatocellular carcinoma policy changes on liver transplantation for hepatocellular carcinoma in the United States.
Shah RH, Chyou D, Goldberg DS
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2022; (28(12)):1857-1864 doi:10.1002/lt.26509.
PMID: 35585774 - 19
Early Impact of MMaT-3 Policy on Liver Transplant Waitlist Outcomes for Hepatocellular Carcinoma.
Shaikh A, Goli K, Rich NE, et al.
Transplantation direct 2022; (8(5)):e1313 doi:10.1097/TXD.0000000000001313.
PMID: 35434283 - 20
Current policy for allocation of donor livers in the Netherlands advantages primary sclerosing cholangitis patients on the liver transplantation waiting list-a retrospective study.
Goet JC, Hansen BE, Tieleman M, et al.
Transplant international : official journal of the European Society for Organ Transplantation 2018; (31(6)):590-599 doi:10.1111/tri.13097.
PMID: 29150966 - 21
Endoscopic management of primary sclerosing cholangitis.
Mizuno S, Uchida Y, Ando S, et al.
Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 2025; (37(7)):723-732 doi:10.1111/den.15010.
PMID: 40049717
This page provides educational information about MELD score exceptions for PSC. It does not replace professional medical advice; always consult your transplant team regarding your waitlist status and specific qualifications.
Get notified when new evidence is published on Primary sclerosing cholangitis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.